title: Pharmacokinetic and dose tolerability study of ADD 94057 in comedicated patients with partial seizures.
abstract: ADD 94057, a metabolite of fluzinamide, manufactured by the A. H. Robins Company, blocks chemically- and electrically-induced seizures in animals. The primary objective of this open add-on study was to evaluate patient tolerability of ADD 94057 at ascending target plasma concentrations. Nine subjects with medically refractory seizures were receiving phenytoin (PHT, 3), carbamazepine (CBZ, 3), or both (3). A pharmacokinetic profile after a single oral 400-mg dose of ADD 94057 was used to calculate ADD 94057 dosages. After a 4-week baseline period, patients were treated for 4 weeks with weekly ADD 94057 dosage escalations. Two patients completed the study at their assigned highest dosage level; the other patients finished the study at lower dosages. The patients receiving PHT (but not CBZ) tolerated higher plasma concentrations of ADD 94057 than did patients receiving CBZ, alone or in combination with PHT. Adverse experiences included headache, ataxia, blurred vision, diplopia, dizziness, lightheadedness, and mild confusion. Eight of nine patients had reductions in seizure frequency from baseline.
authors.affiliation: Epilepsy Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: G W
authors.initials: GW
authors.lastname: Pledger
authors.forename: K D
authors.initials: KD
authors.lastname: Laxer
authors.forename: J T
authors.initials: JT
authors.lastname: Sahlroot
authors.forename: M R
authors.initials: MR
authors.lastname: Taylor
authors.forename: J J
authors.initials: JJ
authors.lastname: Cereghino
authors.forename: C
authors.initials: C
authors.lastname: McCormick
authors.forename: L
authors.initials: L
authors.lastname: Whitley
authors.forename: L W
authors.initials: LW
authors.lastname: Manning
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001384:Azetidines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D002220:Carbamazepine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010672:Phenytoin / Q000494:pharmacology; D011336:Probability
chemical_list: D000927:Anticonvulsants; D001384:Azetidines; D002220:Carbamazepine; D010672:Phenytoin; C064672:AHR 11748